Amgen (AMGN) is facing an antitrust lawsuit in the US filed by Sandoz, accusing Amgen of "extending and entrenching" the leading market position of its Enbrel medicine, also known as etanercept.
Sandoz said Monday that Amgen "blocked competition" from Enbrel biosimilars, including Erelzi from Sandoz, by illegally acquiring and using certain patent rights to entrench its market position.
Enbrel is approved in the US for patients with disabling inflammatory diseases and Sandoz said it received US FDA approval for Erelzi in 2016.
Apart from damages, Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block Enbrel's biosimilar competition and allow it to launch Erelzi, according to the statement.
Amgen did not immediately respond to a request for comment from MT Newswires.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。